tiprankstipranks
Advertisement

RFG - ETF AI Analysis

Compare

Top Page

RFG

Invesco S&P Midcap 400 Pure Growth ETF (RFG)

Rating:73Outperform
Price Target:
RFG, the Invesco S&P Midcap 400 Pure Growth ETF, earns a solid overall rating largely because many of its key holdings—like TechnipFMC, Valaris, Fabrinet, Woodward, and TTM Technologies—show strong financial performance, positive earnings calls, and generally supportive technical trends, which together signal healthy growth potential. However, weaker spots such as Arrowhead Pharmaceuticals and DigitalOcean, where financial challenges, high leverage, or stretched valuations are concerns, slightly weigh on the fund’s appeal, and investors should also note that several top holdings share valuation risks like high P/E ratios or overbought technical signals.
Positive Factors
Strong Recent Performance
The ETF has shown strong gains so far this year and in recent months, indicating solid momentum.
High-Growth Top Holdings
Most of the largest positions have delivered strong year-to-date gains, helping drive the fund’s overall returns.
Sector Diversification Within Growth
Holdings spread across industrials, technology, health care, and several other sectors help reduce the impact if any one industry weakens.
Negative Factors
Mid-Cap Growth Volatility
Because it focuses on mid-size growth companies, the fund may experience larger price swings than more conservative, broad-market ETFs.
Heavy U.S. Exposure
With almost all assets in U.S. stocks, the ETF offers little geographic diversification if the U.S. market struggles.
Moderate Expense Ratio
The fund’s fee is not especially low, which slightly reduces the net return investors keep over time.

RFG vs. SPDR S&P 500 ETF (SPY)

RFG Summary

RFG is the Invesco S&P Midcap 400 Pure Growth ETF, which follows the S&P Mid Cap 400 Pure Growth index. It focuses on medium‑sized U.S. companies that are growing quickly, based on things like rising sales and earnings. The fund holds a mix of sectors, with a lot in industrials, technology, and health care. Examples of companies inside the ETF include TechnipFMC and Arrowhead Pharmaceuticals. Someone might invest in RFG to seek higher long‑term growth than large, slower‑moving companies, while still being diversified across many stocks. A key risk is that mid‑cap growth stocks can be quite volatile and can go up and down sharply with the market.
How much will it cost me?The Invesco S&P Midcap 400 Pure Growth ETF (RFG) has an expense ratio of 0.35%, which means you’ll pay $3.50 per year for every $1,000 invested. This cost is slightly higher than average because the fund is actively managed to focus on mid-cap growth stocks, requiring more research and strategy compared to passively managed ETFs. It’s designed for investors seeking targeted exposure to companies with strong growth potential.
What would affect this ETF?The Invesco S&P Midcap 400 Pure Growth ETF (RFG) could benefit from economic growth and innovation within sectors like Industrials, Health Care, and Technology, which make up a significant portion of its holdings. However, it may face challenges if interest rates rise, as growth stocks often become less attractive in such environments, or if economic uncertainty impacts mid-cap companies more heavily than larger firms. Regulatory changes or sector-specific disruptions could also influence the performance of its top holdings.

RFG Top 10 Holdings

RFG is leaning hard into U.S. mid-cap growth, with a clear tilt toward industrials, tech, and health care names that have been doing much of the heavy lifting. MasTec, Fabrinet, and Rambus have been rising steadily, giving the fund a strong backbone of infrastructure and chip-related growth. Energy player Valaris has also been a powerful engine, despite a recent pause. Arrowhead Pharmaceuticals is more of a wild card—its stock has been mixed as promising drug pipelines clash with financial growing pains, adding some bumpiness to an otherwise strong lineup.
Name
Company Name
Weight %
Market Value
Market Cap
Yearly Gain
Overall Rating
Sterling Infrastructure3.46%$12.26M$27.19B393.30%
71
Outperform
DigitalOcean Holdings2.61%$9.26M$16.80B462.51%
73
Outperform
MasTec2.38%$8.45M$34.24B198.22%
74
Outperform
Arrowhead Pharmaceuticals2.36%$8.37M$11.08B505.97%
57
Neutral
TechnipFMC2.26%$8.01M$29.48B153.83%
80
Outperform
TTM Technologies2.03%$7.20M$17.10B534.94%
77
Outperform
Valaris2.00%$7.08M$6.43B155.72%
76
Outperform
Carpenter Technology1.99%$7.06M$22.76B119.14%
75
Outperform
Rambus1.97%$6.98M$14.06B155.63%
78
Outperform
Woodward1.96%$6.93M$22.79B96.91%
79
Outperform

RFG Technical Analysis

Technical Analysis Sentiment
Positive
Last Price
Price Trends
50DMA
57.48
Positive
100DMA
56.39
Positive
200DMA
53.68
Positive
Market Momentum
MACD
1.11
Negative
RSI
72.30
Negative
STOCH
86.45
Negative
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For RFG, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 59.60, equal to the 50-day MA of 57.48, and equal to the 200-day MA of 53.68, indicating a bullish trend. The MACD of 1.11 indicates Negative momentum. The RSI at 72.30 is Negative, neither overbought nor oversold. The STOCH value of 86.45 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for RFG.

RFG Peer Comparison

Comparison Results
Name
Price
Price Target
AUM
Expense Ratio
Overall Rating
$344.02M0.35%
73
Outperform
$527.75M0.73%
69
Neutral
$358.29M0.31%
69
Neutral
$158.16M0.80%
75
Outperform
$136.47M0.60%
59
Neutral
$114.35M0.85%
68
Neutral
Performance Comparison
Ticker
Company Name
Price
Change
% Change
RFG
Invesco S&P Midcap 400 Pure Growth ETF
63.04
16.98
36.86%
FNY
First Trust Mid Cap Growth AlphaDEX Fund
NUMG
Nuveen ESG Mid-Cap Growth ETF
GLRY
Inspire Faithward Mid Cap Momentum ESG ETF
FRTY
Alger Mid Cap 40 ETF
TMFM
Motley Fool Mid-Cap Growth ETF
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents
Advertisement